Following a landmark **Scheme of Merger by Absorption** approved in **November 2025**, the company has transitioned from a pure investment holding firm into a high-tech operational entity. By merging with its associate, **Innovassynth Technologies (India) Limited (ITIL)**, the listed entity now operates as a research-driven **Contract Development and Manufacturing Organisation (CDMO)** specializing in complex chemistry for life sciences and specialty chemicals. --- ### **Core Business Verticals & Specialized Capabilities** The company’s operations are structured across three high-barrier-to-entry segments, leveraging deep expertise in molecular synthesis: * **Life Sciences & Nucleosides:** A pioneer in India for commercial-scale production of nucleic acid chemistry. This unit focuses on building blocks—**protected Nucleosides and Phosphoramidites**—essential for synthesizing **DNA, RNA, and oligonucleotide-based drugs**. It also develops **ADC (Antibody Drug Conjugate) linkers** and delivery platforms. * **Specialty Intermediates & Organometallics:** This vertical utilizes advanced **organometallic chemistry** and catalyst systems. Key applications include: * **Semiconductors:** Development of **ALD/CVD precursors**. * **Polymers & Petroleum:** Production of **metallocene precursors**, ligands, and polymer additives. * **Performance Chemicals:** Custom manufacturing of specialty reagents, flavors, and fragrances. * **Contract Research Development and Manufacturing (CRDMO):** Provides end-to-end services from concept to commercialization. Using **Full Time Equivalent (FTE)** or **Fee for Services (FFS)** models, the company offers route scouting, process optimization, and scale-up from laboratory to pilot and commercial volumes. --- ### **Strategic Infrastructure & Human Capital** The company operates through integrated facilities designed to meet stringent global standards: * **Manufacturing Hub:** A **60+ acre** complex in **Khopoli, Maharashtra**, housing **9 multipurpose production plants**. * **R&D Excellence:** A state-of-the-art research facility in **Hinjewadi, Pune**, dedicated to custom synthesis and process innovation. * **Technical Workforce:** A total strength of **300+ employees**, including a robust scientific core of **50+ scientists** (**10+ PhDs**) and **100+ technical staff**. * **Sustainability & Compliance:** Holds an **EcoVadis Gold Rating** (2025, 2026) and operates a **Zero Liquid Discharge (ZLD)** system. Certified under **ISO 9001, 14001, 45001**, and **ISO 27001:2022** for information security. --- ### **Market Position & Financial Model** The company’s business model is characterized by high export dependency and long-term global partnerships. * **Global Footprint:** Approximately **90% of revenue** is derived from international markets, primarily the **USA and Europe**. * **Client Ecosystem:** Serves **100+ customers**, including a cornerstone exclusive manufacturing partnership with a leading **German MNC** active since **2002**. * **Supply Chain Dynamics:** To mitigate procurement lead times of **35–45 days**, the company maintains a minimum **60-day inventory** of raw materials. Approximately **40% of materials** are imported, with the **top 10 suppliers** accounting for **51%** of procurement. * **Operational Complexity:** The manufacturing process is intensive, involving **10 to 20 processing steps** for complex molecules, resulting in a capital-intensive working capital cycle. | Key Operational Metric | Value / Detail | | :--- | :--- | | **Export Revenue Share** | **~81.5% (FY26P) to 97.8% (FY27P)** | | **Inventory Holding** | **~60 days** | | **Receivables Cycle** | **~37 days** (Weighted Average) | | **Payables Cycle** | **~62 days** (Weighted Average) | | **Small Molecule Market Share** | **60%–70%** of recently approved global drugs | --- ### **Financial Performance & Projections** Post-merger, the company is in a phase of aggressive scaling, though it currently manages a legacy of accumulated losses. | Metric | Q3 FY26 | YTD FY26 | FY 2026 (Proj) | FY 2027 (Proj) | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | **₹22 Cr** | **₹52 Cr** | **₹100 Cr** | **₹225 Cr** | | **EBITDA** | **₹(4.5) Cr** | **₹(31) Cr** | - | - | | **PAT (Loss)** | **₹(7.5) Cr** | **₹(40.6) Cr** | - | - | | **Revenue Growth** | - | - | **N/A** | **125%** | * **Liquidity Position:** As of December 2025, the **Net Asset Value (NAV)** stood at **₹5.53**. The company has historically faced negative operating cash flows, supported by financing activities. * **Accumulated Losses:** Totaled **₹13.54 Cr** as of December 2024, resulting in no dividend recommendations for recent cycles. --- ### **Capital Restructuring & Growth Strategy** The company is executing a multi-pronged strategy to deleverage and expand capacity: * **The Merger (Dec 2025):** Allotted **4,74,65,031** equity shares in a **1:1 ratio** to ITIL shareholders. Authorized share capital was increased to **₹105 Crore**. * **Rights Issue (April 2026):** Initiated a capital raise of **₹69.65 Crore** (at **₹40 per share**). * **Debt Reduction:** **₹44 Crore** earmarked to fully pre-pay an **ICICI Bank** Rupee Term Loan. * **Growth Capital:** Remaining funds allocated for working capital to support the **125%** projected revenue jump in FY27. * **Capacity Expansion:** Plans for a new **GMP-compliant facility** within **1-2 years** to capture the **17.5% CAGR** in the global oligonucleotide market. * **Promoter Commitment:** Post-restructuring, promoter shareholding is projected to reach **73.7%**, led by **Viren Rajan Raheja** and **Akshay Rajan Raheja**. --- ### **Risk Factors & Mitigation** Investors should note the following critical risks: * **Going Concern & Liquidity:** Auditors have noted material uncertainty due to accumulated losses and current liabilities exceeding current assets. The company relies on the success of the **Rights Issue** and projected revenue growth to stabilize. * **Legal Contingencies:** * **Taxation:** A **₹17.30 crore** Customs/GST appeal regarding pre-import conditions. * **Civil/Criminal:** A **₹9.54 crore** civil suit and a criminal case related to a fatal industrial accident at the Khopoli site. * **Promoter FIR:** An ongoing investigation (FIR 02/2017) alleging fraud/forgery. * **Operational Concentration:** Heavy reliance on a single manufacturing site in **Khopoli** and a concentrated customer base (top 15 clients drive the bulk of revenue). * **Regulatory & Geopolitical:** Vulnerability to **forex fluctuations** and changes in international trade policies in the **USA and Europe**. Compliance with the **Environment Protection Act** and new **Labour Codes** (estimated **₹92.12 lakhs** impact) remains mandatory.